SGI
SYRS

Summit Global Investments’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Summit Global Investments’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,180
Closed -$142K – 629
2021
Q3 		$142K Buy
+3,180
New +$155K 0.01% 452

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Summit Global Investments's SYRS Position: Q4 2021 in Review

Summit Global Investments sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 3,180 shares — an estimated $142K sold.

Summit Global Investments first reported a position in SYRS in Q3 2021 and held it in 1 quarter. The position peaked at $142K in Q3 2021. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

  • Summit Global Investments reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Summit Global Investments sold 3,180 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $142K.
  • Summit Global Investments first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Summit Global Investments's Syros Pharmaceuticals, Inc. Common Stock position peaked at $142K in Q3 2021.
  • 90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Summit Global Investments's 13F filing for Q4 2021, filed 14 Feb 2022.